JP2020522506A5 - - Google Patents

Download PDF

Info

Publication number
JP2020522506A5
JP2020522506A5 JP2019566594A JP2019566594A JP2020522506A5 JP 2020522506 A5 JP2020522506 A5 JP 2020522506A5 JP 2019566594 A JP2019566594 A JP 2019566594A JP 2019566594 A JP2019566594 A JP 2019566594A JP 2020522506 A5 JP2020522506 A5 JP 2020522506A5
Authority
JP
Japan
Prior art keywords
group
psma
tumors
compound
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019566594A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020522506A (ja
JP7821460B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/035220 external-priority patent/WO2018222778A1/en
Publication of JP2020522506A publication Critical patent/JP2020522506A/ja
Publication of JP2020522506A5 publication Critical patent/JP2020522506A5/ja
Priority to JP2023127925A priority Critical patent/JP2023159182A/ja
Priority to JP2024221155A priority patent/JP2025041719A/ja
Application granted granted Critical
Publication of JP7821460B2 publication Critical patent/JP7821460B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019566594A 2017-05-30 2018-05-30 前立腺がんの内部放射線治療法のための前立腺特異的膜抗原をターゲットとした高親和性薬剤 Active JP7821460B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023127925A JP2023159182A (ja) 2017-05-30 2023-08-04 前立腺がんの内部放射線治療法のための前立腺特異的膜抗原をターゲットとした高親和性薬剤
JP2024221155A JP2025041719A (ja) 2017-05-30 2024-12-17 前立腺がんの内部放射線治療法のための前立腺特異的膜抗原をターゲットとした高親和性薬剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762512515P 2017-05-30 2017-05-30
US62/512,515 2017-05-30
PCT/US2018/035220 WO2018222778A1 (en) 2017-05-30 2018-05-30 Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023127925A Division JP2023159182A (ja) 2017-05-30 2023-08-04 前立腺がんの内部放射線治療法のための前立腺特異的膜抗原をターゲットとした高親和性薬剤

Publications (3)

Publication Number Publication Date
JP2020522506A JP2020522506A (ja) 2020-07-30
JP2020522506A5 true JP2020522506A5 (https=) 2021-01-07
JP7821460B2 JP7821460B2 (ja) 2026-02-27

Family

ID=64455570

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019566594A Active JP7821460B2 (ja) 2017-05-30 2018-05-30 前立腺がんの内部放射線治療法のための前立腺特異的膜抗原をターゲットとした高親和性薬剤
JP2023127925A Pending JP2023159182A (ja) 2017-05-30 2023-08-04 前立腺がんの内部放射線治療法のための前立腺特異的膜抗原をターゲットとした高親和性薬剤
JP2024221155A Pending JP2025041719A (ja) 2017-05-30 2024-12-17 前立腺がんの内部放射線治療法のための前立腺特異的膜抗原をターゲットとした高親和性薬剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023127925A Pending JP2023159182A (ja) 2017-05-30 2023-08-04 前立腺がんの内部放射線治療法のための前立腺特異的膜抗原をターゲットとした高親和性薬剤
JP2024221155A Pending JP2025041719A (ja) 2017-05-30 2024-12-17 前立腺がんの内部放射線治療法のための前立腺特異的膜抗原をターゲットとした高親和性薬剤

Country Status (5)

Country Link
US (2) US11478558B2 (https=)
EP (1) EP3630733A4 (https=)
JP (3) JP7821460B2 (https=)
CN (2) CN118146170A (https=)
WO (1) WO2018222778A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250126870A (ko) * 2018-02-06 2025-08-25 더 존스 홉킨스 유니버시티 암 방사선 치료를 위한 psma 표적 방사성 할로겐화 우레아-폴리아미노카복실레이트
CA3137963A1 (en) * 2019-04-26 2020-10-29 Five Eleven Pharma Inc. Prostate-specific membrane antigen (psma) inhibitors as diagnostic and radionuclide therapeutic agents
CN120441497A (zh) * 2019-07-02 2025-08-08 先进加速器应用意大利公司 前列腺特异性膜抗原（psma）配体及其用途
WO2021001362A1 (en) * 2019-07-02 2021-01-07 Advanced Accelerator Applications (Italy) Srl Prostate specific membrane antigen (psma) ligands and uses thereof
WO2021202376A1 (en) * 2020-03-30 2021-10-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for blocking uptake of prostate-specific membrane antigen (psma)-targeted radionuclides by exocrine organs
CA3176404A1 (en) * 2020-04-24 2021-10-28 Ebrahim S. Delpassand Composition, kit and method for diagnosis and treatment of prostate cancer
MX2022013783A (es) * 2020-05-06 2023-04-19 Univ Cornell Compuestos tratanosticos que contienen cobre y metodos de uso.
KR20240004205A (ko) 2020-07-13 2024-01-11 포인트 바이오파마 인코포레이티드 방사성의약 및 방법
EP4196175A4 (en) * 2020-08-14 2025-07-30 Clarity Pharmaceuticals Ltd RADIOPHARMACEUTICAL COMPOUNDS, THEIR USES AND PROCESSES FOR THEIR PRODUCTION
US20230338587A1 (en) * 2020-08-31 2023-10-26 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
WO2022043556A1 (en) * 2020-08-31 2022-03-03 Novartis Ag Stable radiopharmaceutical composition
US20230321285A1 (en) * 2020-08-31 2023-10-12 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
JP2023552383A (ja) * 2020-12-04 2023-12-15 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ペプチド受容体放射性核種療法
CN113077840B (zh) * 2021-04-21 2023-01-31 四川大学 基于药效团与alpha-碳特征的金属酶活性位点对比方法
EP4475900A1 (en) * 2022-02-09 2024-12-18 Novartis AG Pharmaceutical compositions comprising a 225-actinium-labelled complex and a bismuth sequestering agent
EP4536278A2 (en) * 2022-06-07 2025-04-16 Actinium Pharmaceuticals, Inc. Bifunctional chelators and conjugates
EP4667019A1 (en) * 2023-02-16 2025-12-24 Norroy Bioscience Co., Ltd. Psma-targeted radiopharmaceutical, and synthesis and use thereof
WO2024243315A2 (en) * 2023-05-22 2024-11-28 Actinium Pharmaceuticals, Inc. Multi-arm bifunctional chelators

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2926573C (en) * 2007-06-26 2018-08-28 The Johns Hopkins University Labeled inhibitors of prostate specific membrane antigen (psma), biological evaluation, and use as imaging agents
WO2009070302A1 (en) 2007-11-30 2009-06-04 The Johns Hopkins University Prostate specific membrane antigen (psma) targeted nanoparticles for therapy of prostate cancer
TW201034691A (en) * 2008-12-05 2010-10-01 Molecular Insight Pharm Inc Technetium-and rhenium-bis(heteroaryl) complexes and methods of use thereof
EP3222617B1 (en) 2009-03-19 2022-07-06 The Johns Hopkins University Psma-targeting compounds and uses thereof
WO2013022797A1 (en) * 2011-08-05 2013-02-14 Molecular Insight Pharmaceuticals Radiolabeled prostate specific membrane antigen inhibitors
CN113149921B (zh) * 2011-11-30 2024-11-29 约翰霍普金斯大学 前列腺特异性膜抗原(psma)的同源多价抑制剂和异源多价抑制剂以及其用途
EP3300746B1 (en) * 2013-01-14 2019-05-15 Molecular Insight Pharmaceuticals, Inc. Triazine based radiopharmaceuticals and radioimaging agents
EP2862857A1 (en) * 2013-10-18 2015-04-22 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
LT4095130T (lt) * 2013-10-18 2024-04-25 Novartis Ag Žymėti prostatos specifinio membranos antigeno (psma) inhibitoriai, jų naudojimas kaip vizualizavimo medžiagų ir farmacinių medžiagų prostatos vėžiui gydyti
AU2015256002B2 (en) * 2014-05-06 2020-01-02 Northwestern University Metal/radiometal-labeled PSMA inhibitors for PSMA-targeted imaging and radiotherapy
EP3183236B1 (en) * 2014-08-24 2022-04-20 Max-Planck-Gesellschaft zur Förderung der Wissenschaften Method for the production of 18f-labeled active esters and their application exemplified by the preparation of a psma-specific pet-tracer
AU2015315465B2 (en) * 2014-09-08 2019-08-29 Molecular Insight Pharmaceuticals, Inc. Organ protection in PSMA-targeted radionuclide therapy of prostate cancer
US11420910B2 (en) * 2014-10-30 2022-08-23 Katholieke Universitet Leuven Methods for low temperature fluorine-18 radiolabeling of biomolecules
US10688200B2 (en) * 2015-12-31 2020-06-23 Five Eleven Pharma Inc. Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy
HRP20240215T1 (hr) 2016-03-22 2024-04-26 The Johns Hopkins University Sredstva sa visokim afinitetom za ciljani učinak na membranski antigen specifičan za prostatu za endoradioterapiju raka prostate

Similar Documents

Publication Publication Date Title
JP7821460B2 (ja) 前立腺がんの内部放射線治療法のための前立腺特異的膜抗原をターゲットとした高親和性薬剤
JP2020522506A5 (https=)
JP7630149B2 (ja) Ｐｓｍａを標的としたイメージング及び放射線治療のための金属／放射性金属標識ｐｓｍａ阻害剤
JP7073270B2 (ja) 前立腺がんの内部放射線療法のための前立腺特異的膜抗原を標的とした高親和性薬剤
US20250057993A1 (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancers
CN110612126B (zh) 可用于成像和抗肿瘤治疗的具有可调的药代动力学的三功能构建体
EP3609544B1 (en) Prodrugs of 2-pmpa for healthy tissue protection during psma-targeted cancer imaging or radiotherapy
US20230285603A1 (en) Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies
KR20230165818A (ko) 섬유아세포 활성화 단백질 알파 및/또는 전립선-특이적 막 항원을 표적화하는 이종이가 및 동형이가 제제
US20210040126A1 (en) 68Ga-LABELED NOTA-CHELATED PSMA-TARGETED IMAGING AND THERAPEUTIC AGENTS
WO2016065145A2 (en) Psma targeted reversed carbamates and methods of use thereof
WO2016149188A1 (en) 68Ga-LABELED NOTA-CHELATED PSMA-TARGETED IMAGING AND THERAPEUTIC AGENTS
CN115745903B (zh) 一种肽脲素衍生物、含其的药物组合物及其应用
WO2025042989A1 (en) Psma-based albumin binding agents for targeted radionuclide therapy of prostate cancer
HK40019820B (zh) 可用於成像和抗肿瘤治疗的具有可调的药代动力学的三功能构建体